Ian Campbell

The impact of coding germline variants on contralateral breast cancer risk and survival.

Anna Morra, Nasim Mavaddat, Taru A Muranen, Thomas U Ahearn, Jamie Allen, Irene L Andrulis, Päivi Auvinen, Heiko Becher, Sabine Behrens, Carl Blomqvist, Stig E Bojesen, Manjeet K Bolla, Hiltrud Brauch, Nicola J Camp, Sara Carvalho, Jose E Castelao, Melissa H Cessna, Jenny Chang-Claude, Georgia Chenevix-Trench, undefined NBCS Collaborators, et al.

Journal article  |  2023  |  Am J Hum Genet

Evidence linking coding germline variants in breast cancer (BC)-susceptibility genes other than BRCA1, BRCA2, and CHEK2 with contr..

Molecular Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene.

Caitlin T Fierheller, Wejdan M Alenezi, Corinne Serruya, Timothée Revil, Setor Amuzu, Karine Bedard, Deepak N Subramanian, Eleanor Fewings, Jeffrey P Bruce, Stephenie Prokopec, Luigi Bouchard, Diane Provencher, William D Foulkes, Zaki El Haffaf, Anne-Marie Mes-Masson, Marc Tischkowitz, Ian G Campbell, Trevor J Pugh, Celia MT Greenwood, Jiannis Ragoussis, et al.

Journal article  |  2023  |  Genes (Basel)

FANCI was recently identified as a new candidate ovarian cancer (OC)-predisposing gene from the genetic analysis of carriers of FA..

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

Nicola S Meagher, Kylie L Gorringe, Matthew Wakefield, Adelyn Bolithon, Chi Nam Ignatius Pang, Derek S Chiu, Michael S Anglesio, Kylie-Ann Mallitt, Jennifer A Doherty, Holly R Harris, Joellen M Schildkraut, Andrew Berchuck, Kara L Cushing-Haugen, Ksenia Chezar, Angela Chou, Adeline Tan, Jennifer Alsop, Ellen Barlow, Matthias W Beckmann, Jessica Boros, et al.

Journal article  |  2022  |  CLINICAL CANCER RESEARCH

PURPOSE: Advanced-stage mucinous ovarian carcinoma (MOC) has poor chemotherapy response and prognosis and lacks biomarkers to aid ..

Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.

Amber A DeVries, Joe Dennis, Jonathan P Tyrer, Pei-Chen Peng, Simon G Coetzee, Alberto L Reyes, Jasmine T Plummer, Brian D Davis, Stephanie S Chen, Felipe Segato Dezem, Katja KH Aben, Hoda Anton-Culver, Natalia N Antonenkova, Matthias W Beckmann, Alicia Beeghly-Fadiel, Andrew Berchuck, Natalia V Bogdanova, Nadja Bogdanova-Markov, James D Brenton, Ralf Butzow, et al.

Journal article  |  2022  |  J Natl Cancer Inst

BACKGROUND: Known risk alleles for epithelial ovarian cancer (EOC) account for approximately 40% of the heritability for EOC. Copy..

Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants

Belle WX Lim, Na Li, Sakshi Mahale, Simone M McInerny, Magnus Zethoven, Simone M Rowley, Joanne Huynh, Theresa Wang, Jue Er Amanda Lee, Mia Friedman, Lisa Devereux, Rodney J Scott, Erica K Sloan, Paul A James, Ian G Campbell

Journal article  |  2022  |  JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

BACKGROUND: Breast cancers (BCs) that arise in individuals heterozygous for a germline pathogenic variant in a susceptibility gene..

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.

Christopher Hakkaart, John F Pearson, Louise Marquart, Joe Dennis, George AR Wiggins, Daniel R Barnes, Bridget A Robinson, Peter D Mace, Kristiina Aittomäki, Irene L Andrulis, Banu K Arun, Jacopo Azzollini, Judith Balmaña, Rosa B Barkardottir, Sami Belhadj, Lieke Berger, Marinus J Blok, Susanne E Boonen, Julika Borde, Angela R Bradbury, et al.

Journal article  |  2022  |  Commun Biol

The contribution of germline copy number variants (CNVs) to risk of developing cancer in individuals with pathogenic BRCA1 or BRCA..

Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial

Sarah Glewis, Marliese Alexander, Senthil Lingaratnam, Benjamin Lee, Ian Campbell, Mei Krishnasamy, Maarten IJzerman, Mussab Fagery, Sam Harris, Chloe Georgiou, Craig Underhill, Mark Warren, Robert Campbell, Jennifer Martin, Jeanne Tie, Michael Michael

Journal article  |  2022  |  ACTA ONCOLOGICA

The Clinical and Psychosocial Outcomes for Women Who Received Unexpected Clinically Actionable Germline Information Identified through Research: An Exploratory Sequential Mixed-Methods Comparative Study

Laura E Forrest, Rowan Forbes Shepherd, Erin Tutty, Angela Pearce, Ian Campbell, Lisa Devereux, Alison H Trainer, Paul A James, Mary-Anne Young

Journal article  |  2022  |  JOURNAL OF PERSONALIZED MEDICINE

Background Research identifying and returning clinically actionable germline variants offer a new avenue of access to genetic info..

Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression

Dane Cheasley, Marta Llaurado Fernandez, Martin Kobel, Hannah Kim, Amy Dawson, Joshua Hoenisch, Madison Bittner, Derek S Chiu, Aline Talhouk, C Blake Gilks, Madawa W Jayawardana, Kathleen Pishas, Anne-Marie Mes-Masson, Diane Provencher, Abhimanyu Nigam, Neville F Hacker, Kylie L Gorringe, Ian G Campbell, Mark S Carey

Journal article  |  2022  |  NPJ PRECISION ONCOLOGY

Hormone receptor expression is a characteristic of low-grade serous ovarian carcinoma (LGSOC). Studies investigating estrogen rece..

Abstract 43: Predictive biomarkers of recurrence may not be useful for deescalating treatment of breast ductal carcinoma in situ due to de novo ipsilateral breast carcinoma development

Tanjina Kader, Sakshi Mahale, Magnus Zethoven, Hugo Saunders, Dorothea Lesche, David Byrne, Siqi Lai, Lauren Tjoeka, Claire Candido, Maree Pechlevanis, Olivia Craig, Jia-Min Pang, Lisa Devereux, Shona Hendry, Eloise House, Sureshni Jayasinghe, Michael Toss, Islam M Miligy, Emad Rakha, Stephen Fox, et al.

Journal article  |  2022  |  Cancer Research

Abstract Introduction: Up to 25% of cases of ductal carcinoma in situ (DCIS) recur, and half of these recur as inva..